Overview of Maxrelax

Quick Facts

Property	Description
Active ingredient	Thiocolchicoside (INN)
Forms	Oral (tablet/capsule), Injectable solution, Topical (cream/gel)
Pharmacological class	Centrally acting muscle relaxant / Spasmolytic agent
Common use	Relief of painful muscle spasms and rigidity
Origin	Semi-synthetic (derived from Colchicine)

Identity, Class, and Composition

Maxrelax is a pharmaceutical product containing the active ingredient Thiocolchicoside (INN), which is classified as a centrally acting muscle relaxant and a spasmolytic agent. This pharmacological identity signifies that its primary action is mediated through the central nervous system to reduce excessive muscle tone. The compound itself is a semi-synthetic glucoside, establishing a unique origin as it is derived from the naturally occurring substance Colchicine but chemically refined for its specific therapeutic effect. This classification reflects its action on the central pathways that control muscle tension.

Forms, Delivery, and General Purpose

The medication is offered in diverse pharmaceutical preparations, including common oral forms (tablets or capsules) and a sterile injectable solution for intramuscular administration, alongside topical preparations such as cream or gel. This versatility allows for both systemic and localized application. The general purpose of Maxrelax is to promote myorelaxation by modulating inhibitory signals in the central nervous system, notably at the GABAA and glycine receptors. This mechanism is intended to alleviate the painful muscle spasms and rigidity that commonly accompany various musculoskeletal disorders.

What side effects are possible with Maxrelax?

Possible side effects and safety information

The official regulatory safety profile for Maxrelax (Thiocolchicoside) defines adverse reactions based on their frequency and the system-organ classes affected, strictly according to governmental documentation.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by their likelihood of occurrence in clinical use:

Common Reactions may include effects on the nervous system, such as drowsiness (somnolence), along with gastrointestinal effects like diarrhoea and gastralgia (stomach pain).
Uncommon Reactions involve gastrointestinal issues such as nausea and vomiting, as well as skin reactions including pruritus (itching) and maculopapular eruptions.
Rare Reactions are associated primarily with the immune system, such as urticaria (hives).

Reactions with Frequency Unknown include serious events reported post-marketing, such as severe anaphylactic shock, seizure or relapsed attacks in epileptic patients, and hepatobiliary disorders like cytolytic or cholestatic hepatitis.

Safety-Related Restrictions and Contraindications

A major regulatory constraint involves the drug's metabolite, which is linked to a potential risk of aneuploidy. Due to this risk, the medication is contraindicated throughout pregnancy, during breast-feeding, and for women of childbearing potential who are not using effective contraception. Use at doses exceeding recommended levels or long-term use should be avoided as a precautionary measure.

Serious cases of fulminant hepatitis have been reported when the medicine is taken concurrently with non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol. The medicine is generally not recommended for children and adolescents under 16 years of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Maxrelax (Thiocolchicoside) overdose is defined by the acute risk of Central Nervous System (CNS) toxicity, as detailed in authoritative government prescribing information.

Suspected overdose is primarily associated with severe CNS depression and specific clinical signs. Documented manifestations include a confusional state and loss of consciousness. Less severe, yet documented, presentations may include excessive drowsiness (somnolence) and vomiting.

Official Emergency Requirements

Element	Regulatory Mandate
Urgent Medical Action	Seek immediate medical attention upon suspicion of overdose. Contact emergency services immediately if severe symptoms, such as loss of consciousness or seizures, are observed.
Antidote Status	No specific antidote is known for Maxrelax overdose, as documented in official labeling.
Management Measures	Treatment is restricted to symptomatic and supportive measures. Hospital monitoring is often required for continuous observation of vital functions and neurological status.

This structure establishes that the primary risk is neurological, necessitating prompt medical assistance. Since no specific antidote is available, management is strictly supportive until the patient stabilizes.

Therapeutic Uses of Maxrelax

What Maxrelax Treats: Main Uses and Benefits

Maxrelax is utilized to manage specific symptoms linked to certain neurological and musculoskeletal conditions. The medication is a therapeutic option for clinical scenarios involving muscle spasticity, muscle rigidity, and associated painful spasms.

Approved uses include the symptomatic management of spasticity in the context of multiple sclerosis, spasticity related to spinal cord injuries, and for addressing muscle hypertonia of cerebral origin. The intent of this medication is to help reduce elevated muscle tension, which may contribute to enhanced comfort and improved potential for daily physical function.

Quick Fact: Relief for Spasticity and Muscle Rigidity

Eligibility and Restrictions for Use

Who Can and Cannot Use Maxrelax?

The eligibility to use Maxrelax (Thiocolchicoside) is strictly defined by regulatory authorities and is subject to significant restrictions based on age, reproductive status, and pre-existing health conditions. Use is permitted only for adults and adolescents from 16 years onwards for the short-term adjuvant treatment of painful muscle contractures in acute spinal pathology.

Absolute Contraindications (Must Not Use)

Population / Condition	Restriction Basis (Regulatory)
Pediatric Population	Contraindicated in children and adolescents under 16 years of age.
Pregnancy	Contraindicated during the entire pregnancy period and lactation.
Women of Childbearing Potential	Must not be used by women who are not using effective contraception.
Hypersensitivity	Known allergy to Thiocolchicoside or to any of the product's excipients.

Condition-Specific Limitations

Use requires special consideration and caution in patients with a history of epilepsy or risk of seizures, where treatment must be immediately discontinued upon seizure occurrence. Furthermore, specific excipient-linked conditions, such as galactose intolerance, render patients ineligible for certain oral formulations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section details the officially documented interaction patterns of Thiocolchicoside (Maxrelax) as identified in government regulatory prescribing information. The interaction profile is structured around drug class co-administration risks and mandatory metabolite-driven restrictions.

Pharmacodynamic Potentiation and Hepatotoxicity Risk

Co-administration of Thiocolchicoside with other centrally acting muscle relaxants is officially not recommended due to the potential for these agents to increase one another's impact through a pharmacodynamic potentiation. Caution is also advised when using medications that affect smooth muscles, as this combination may elevate the incidence rate of side effects. Furthermore, official post-marketing reports cite serious cases of liver conditions, including fulminant hepatitis, in patients taking Thiocolchicoside concomitantly with agents such as Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or Paracetamol (Acetaminophen).

Metabolite-Driven Regulatory Prohibitions

The product is contraindicated in specific populations due to exposure risks from its metabolite, SL59.0955 (M2), which carries a documented aneuploidy risk. Therefore, Thiocolchicoside must not be used by pregnant women, breastfeeding women, or women of childbearing potential not using effective contraception. The medication may also predispose to seizures in patients with epilepsy or other seizure risk factors, requiring clinical monitoring. No mandatory time separation rules for administration with other medicines or food are documented in the regulatory label.

Mechanism of Action

Central Modulation of Motor Reflexes

The mechanism involves the sites of interaction located in the central nervous system (CNS), specifically targeting the GABA Type A Receptors (GABAAR) and Glycine Receptors (GlyRs) within the spinal cord and brainstem. By modulating the activity of these inhibitory receptors, the drug influences the signaling pathways responsible for motor reflex excitability, resulting in attenuated signaling associated with motor hyperexcitability and reduced motor output.

Interference with Inflammatory Signaling

The drug also engages a secondary, non-neural mechanism by acting as an inhibitor of the cellular activation of Nuclear Factor-kappa B (NF-kappa B), a crucial transcription factor. This molecular interference suppresses the cellular machinery that produces pro-inflammatory mediators, leading to a diminished release of pro-inflammatory mediators and subsequent chemical signaling.

Dual Action and Physiological Synergy

Thiocolchicoside’s action is defined by this dual mechanism, where the central modulation of motor output is physiologically complemented by the peripheral interference with the inflammatory cascade. This combined influence on both the neurological and inflammatory pathways allows for coordinated modulation of the key systems that define the drug's mechanism of action.

Dosage and Administration Information

How to Use Maxrelax (Thiocolchicoside)

Maxrelax (Thiocolchicoside) is used under a strictly defined protocol. The medication is available for systemic use via oral forms (tablets/capsules) and intramuscular (IM) injection, as well as for local application through topical preparations. Systemic use is recommended only as adjuvant treatment for painful muscle contractures, such as those related to acute spinal pathology.

Usage is characterized by mandatory dose maximums and time limits. Both systemic routes are restricted to a twice-daily frequency (every 12 hours).

Route	Maximum Single Dose	Maximum Daily Dose	Maximum Duration
Oral	8 mg	16 mg	7 consecutive days
IM Injection	4 mg	8 mg	5 consecutive days

The duration of treatment is strictly limited; oral use should not exceed seven consecutive days, while IM injection use must not exceed five consecutive days. Furthermore, systemic administration is restricted to individuals 16 years of age and older, and the medication is not recommended for children younger than 16. Oral forms, such as capsules or tablets, are generally taken by swallowing with a glass of water. The established administration schedule emphasizes that doses must not exceed the stated maximums, and long-term use is to be avoided.

Recent Clinical Evidence

Maxrelax: Recent Clinical Evidence

Evidence for Use in Acute Painful Muscle Spasms

The primary research for Maxrelax was evaluated in studies that focused on patients experiencing sudden and painful muscle contractures, such as those related to acute low back spasms. This evidence is largely derived from short-term randomized controlled trials (RCTs) and systematic reviews. Researchers monitored changes in patient-reported outcomes related to physical discomfort and daily functioning in adult populations. Studies reported measurements of pain levels and mobility changes recorded over a short observation period. Findings describe patterns observed in these studies, helping to contextualize patient experience during a brief course of use.

Comparative Research and Study Design

Research evaluated Maxrelax in studies where it was compared against a placebo (an inactive substance) or to other active control treatments. The evidence base includes many instances where Maxrelax was studied as part of a combination therapy, typically alongside other standard pain medications. Systematic reviews found that some original trials were assessed to have a high risk of bias, which contributes to uncertainty regarding their conclusions. Comparative evidence is lacking for many direct head-to-head comparisons against other single-agent spasmolytics.

Long-Term Outcomes and Follow-up Duration

The available evidence provides limited insight into long-term effects. Research explored short-term symptom changes, but most key studies monitored patient responses over defined time intervals that were typically short, often spanning only three to seven days. As a result, there is limited information for long-term outcomes, and the durability of any observed changes in physical discomfort over extended periods is not fully established. Research does not determine whether an individual will respond similarly over time.

Evidence in Specific Patient Groups and Research Gaps

Research examined patient populations that were primarily adults without severe comorbidities. Consequently, the results apply only to the populations studied, and data for certain groups remain insufficient. For example, there is limited information available from regulatory or peer-reviewed sources for use in children, adolescents, or older adults. The overall evidence level for use in acute spasms is often categorized as Moderate by scientific reviewers, though its quality is frequently questioned due to methodological constraints. The evidence helps contextualize what is known — and what remains uncertain — regarding the consistency of measured changes.

Key Studies & References Efficacy and Safety of the Combination of Diclofenac and Thiocolchicoside in the Treatment of Low Back Pain and Other Conditions: Systematic Review of the Literature

Frequently Asked Questions (FAQ)

Common questions about Maxrelax (FAQ)

Q: Can older adults use Maxrelax safely?

A: Official documents indicate that the available clinical data regarding Maxrelax is limited for use in older adults. While the drug is officially permitted for individuals 16 years of age and older, the information highlights a research gap concerning the drug's safety profile specifically in the elderly population.

Q: Are there any known interactions between Maxrelax and common supplements like vitamins?

A: Regulatory information advises caution regarding co-administration with products, including certain herbal supplements, that may possess central nervous system (CNS) depressant properties. This warning is due to the potential for these products to increase the risk of drowsiness when combined with Maxrelax.

Q: How long does the primary effect of Maxrelax typically last?

A: The duration of the drug's effect is informed by regulatory documentation that reports the active metabolite has a half-life of approximately 7.3 hours. This short pharmacological half-life aligns with the drug's recommended use schedule.

Q: Can Maxrelax be used by people who have liver problems?

A: Official product information indicates that use of Maxrelax is subject to special considerations for patients with any degree of liver impairment. The drug is generally not recommended for use by patients who have severe liver disease.

Q: Is the effect of Maxrelax immediate or does it build up over time?

A: Maxrelax is officially indicated for the short-term adjuvant treatment of acute painful muscle conditions, suggesting an acute rather than gradual therapeutic effect. Regulatory documents report that the active metabolite of the drug is detectable in the body within approximately one hour after the oral dose.

Q: Is Maxrelax known to interact with common cold or flu medications?

A: Official safety documents report a risk of serious liver toxicity (hepatotoxicity) when Maxrelax is taken concomitantly with nonsteroidal anti-inflammatory drugs (NSAIDs) or Paracetamol (Acetaminophen). Because these components are common in many cold and flu remedies, this potential interaction is highlighted in regulatory materials.

Q: What is the purpose of Maxrelax if it is not used for pain relief?

A: The purpose of Maxrelax is officially defined as the relief of painful muscle contractures and rigidity. It is classified as an adjuvant treatment for acute painful conditions, meaning its function is to address the specific source of discomfort caused by muscle tension.

Q: How long does it usually take to feel the effect of Maxrelax after taking it?

A: Regulatory pharmacokinetic studies describe the time it takes for the drug to enter the system. The active metabolite is detectable in the body approximately 1 hour after an oral dose, and within 30 to 60 minutes following an intramuscular injection.

Q: Can Maxrelax be taken on an empty stomach?

A: Official regulatory guidance for the oral formulation describes taking Maxrelax with or immediately after food. This instruction is included to help reduce the possibility of stomach irritation or upset.

Q: Is Maxrelax known to cause dependence or withdrawal symptoms?

A: Maxrelax is a centrally acting agent, and its use is strictly limited to a short, defined period. Regulatory documentation emphasizes avoiding long-term use and higher doses, but it is not universally classified as a federally controlled substance.

Q: Does taking Maxrelax affect how long it stays in your system?

A: Pharmacokinetic studies indicate that the active metabolite (M1) is eliminated from the body with an approximate half-life of 7.3 hours. This half-life describes the time it takes for the concentration of the substance to decrease by half in the system.

Q: Is Maxrelax considered a controlled substance?

A: Regulatory systems generally classify Maxrelax (Thiocolchicoside) as a prescription-only medication (℞). While the drug is centrally acting, official drug classification databases do not universally list it as a federally controlled substance with potential for abuse.

Q: Is it normal to feel a mild headache when first starting Maxrelax?

A: A headache is an effect that is listed in the official regulatory safety profile of Maxrelax. Side effects are categorized by frequency, and headache is described as a commonly reported effect.

Q: What should I do if a rare side effect is experienced while taking Maxrelax?

A: Official regulatory guidance describes that the occurrence of rare or serious side effects requires the patient to immediately discontinue the medication. It is further indicated that prompt medical attention must be sought for professional evaluation and to ensure proper reporting of the event.

Q: Can Maxrelax interact with birth control pills?

A: Official regulatory documents do not state that Maxrelax affects the effectiveness of oral contraceptives themselves. However, Maxrelax is contraindicated (use is prohibited) for women of childbearing potential who are not using effective contraception due to a documented risk to the fetus from the drug's metabolite.

Q: Can people with kidney conditions take Maxrelax?

A: Official regulatory materials state that the use of Maxrelax is subject to special considerations for patients with any degree of kidney (renal) impairment. The drug is generally not recommended for patients who have severe kidney disease.

Q: Do official documents mention Maxrelax interacting with alcohol?

A: Official documents explicitly address the use of alcohol while using Maxrelax. The combination is described as enhancing the drug's central nervous system depressant effects, which increases the risk of excessive drowsiness and sedation.

Q: Are there any known issues with abruptly stopping Maxrelax use?

A: Maxrelax is officially indicated only for a strictly limited, short duration of use. Because the treatment period is defined as short, regulatory materials do not detail a specific protocol for tapering or cessation.

How should Maxrelax be stored and disposed of?

Maxrelax must be stored at the controlled room temperature range specified in the official labeling, which generally requires storage below 25 C or 30 C to maintain stability. The product should be kept in its original container and must be protected from both light and moisture. Certain forms, such as injectable solutions, are explicitly prohibited from being frozen. To prevent accidental ingestion, the medication must be stored out of the sight and reach of children.

Disposal of unused or expired Maxrelax must follow local regulations for pharmaceutical waste. The preferred method is utilizing a drug take-back program or authorized collection point. The product should not be discarded into wastewater (flushed down the toilet or poured down the sink) unless explicitly advised on the drug's official label.

Maxrelax